Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gazyva
Pharma
Roche's Gazyva chases new kidney disease use with phase 3 win
Roche's Genentech and Biogen have a U.S. partnership for the drug, which scored its first approval in 2013 for chronic lymphocytic leukemia.
Zoey Becker
Sep 26, 2024 11:30am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm
FDA probes TG Therapeutics' Ukoniq for potential death risks
Feb 7, 2022 9:53am
Roche lands approval to slash Gazyvaro infusion time in EU
Oct 19, 2021 7:10am
AbbVie, J&J eye new Imbruvica CLL use in fixed-duration combo
Jun 12, 2021 3:00am
Roche touts phase 2 Gazyva data in lupus nephritis
Jun 11, 2019 2:40pm
